ストックスクリーナーアプリを入手
50.96
0.62%
-0.32
アフターアワーズ：
51.04
0.08
+0.16%
前日終値:
$51.28
開ける：
$51.67
24時間の取引高:
6.27M
Relative Volume:
0.60
時価総額：
$20.21B
収益：
$1.94B
当期純損益:
$-2.82B
株価収益率:
-7.0176
EPS:
-7.2617
ネットキャッシュフロー:
$-2.08B
1週間 パフォーマンス:
+3.58%
1か月 パフォーマンス:
-7.31%
6か月 パフォーマンス:
+89.94%
1年 パフォーマンス:
+108.00%
1日の値動き範囲:
$50.02
$52.89
1週間の範囲:
$47.40
$52.89
52週間の値動き範囲:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
50.96 | 20.34B | 1.94B | -2.82B | -2.08B | -7.2617 |
VRTX
Vertex Pharmaceuticals Inc
|
436.27 | 113.64B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.87 | 81.18B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
799.65 | 49.78B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
322.11 | 42.87B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.66 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 再開されました | Barclays | Equal Weight |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-12 | 開始されました | Jefferies | Hold |
| 2025-03-13 | 開始されました | Citigroup | Neutral |
| 2025-02-18 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-01-29 | ダウングレード | Goldman | Buy → Neutral |
| 2024-12-18 | ダウングレード | Argus | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-19 | 開始されました | Berenberg | Hold |
| 2024-11-18 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-09-13 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-09-13 | ダウングレード | Jefferies | Buy → Hold |
| 2024-09-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-08-28 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-08-07 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-08-05 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-01-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 開始されました | Canaccord Genuity | Hold |
| 2023-11-03 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-11-02 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-08-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-06-26 | アップグレード | UBS | Neutral → Buy |
| 2023-04-26 | 開始されました | Guggenheim | Neutral |
| 2023-03-13 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-02-24 | ダウングレード | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | アップグレード | Jefferies | Hold → Buy |
| 2022-12-14 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2022-01-26 | アップグレード | Deutsche Bank | Sell → Hold |
| 2022-01-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 開始されました | UBS | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-11-09 | 開始されました | Wolfe Research | Outperform |
| 2021-10-22 | 開始されました | Deutsche Bank | Sell |
| 2021-10-15 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-08-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 繰り返されました | Jefferies | Hold |
| 2021-02-01 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-12-16 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | ダウングレード | Needham | Buy → Hold |
| 2020-11-23 | 開始されました | Wells Fargo | Equal Weight |
| 2020-11-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-07-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 開始されました | Jefferies | Buy |
| 2020-06-30 | 開始されました | Argus | Buy |
| 2020-06-08 | 開始されました | Barclays | Overweight |
| 2020-04-30 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-05 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 再開されました | BofA/Merrill | Buy |
| 2019-10-25 | 開始されました | ROTH Capital | Buy |
| 2019-04-05 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Moderna Inc (MRNA) 最新ニュース
Promising Biotech Stocks To Follow TodayApril 10th - MarketBeat
Moderna, Inc. $MRNA Shares Bought by Douglas Lane & Associates LLC - MarketBeat
What is behind Moderna stock's recent drop in value today - Traders Union
Moderna Inc (MRNA) Stock Price Quote Today & Current Price Chart - Capital.com
MODERNA, INC. (MRNA) - MSN
Moderna (MRNA) Experiences Bullish Trading Activity - GuruFocus
Moderna Flu And RSV Data Highlight Push Beyond COVID And Valuation Tension - Yahoo Finance
Looks Like M&A Week in 3 Different Sectors - The Motley Fool
Moderna Is Most Shorted S&P 500 Stock Now. Is It a Contrarian Buy? - Yahoo Finance
Moderna eyes international markets as growth driver, says Bank of America - Proactive financial news
Moderna, Inc. (MRNA) stock price, news, quote and history - Yahoo Finance UK
(MRNA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Messenger RNA (mRNA) Market Projected to Reach $20.99 - GlobeNewswire
Moderna stock consolidates as short-term sellers dominate near $53.35 resistance - Traders Union
RBC Adjusts Price Target on Moderna to $35 From $30, Maintains Sector Perform Rating - marketscreener.com
Spikevax Vaccine: Key Role in mRNA COVID Protection - AD HOC NEWS
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 - Investing News Network
New Moderna data tests repeat flu and RSV shots in older adults - Stock Titan
Moderna (MRNA) CFO vests RSUs, 703 shares withheld for tax - Stock Titan
Moderna: Speculative Buy For Aggressive Investors Betting On mRNA's Future (NASDAQ:MRNA) - Seeking Alpha
Jim Cramer Discusses the Moderna Rally and the Impact of FDA Leadership Changes - Insider Monkey
Is Moderna (MRNA) Pricing Make Sense After A 96% One Year Share Price Jump - Yahoo Finance
Moderna Inc (MRNA) - MSN
Top Moderna Shareholders - Investopedia
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know - Yahoo Finance
Moderna (MRNA) stock dips while market gains: Key facts - MSN
Moderna says the FDA will consider its new flu shot after resolving a public dispute - Dayton Daily News
Moderna (MRNA) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Moderna (NASDAQ:MRNA) Target Update Sparks Nasdaq 100 Index Focus - Kalkine Media
Barclays Analyst Raises Price Target for Moderna (MRNA) to $48.0 - GuruFocus
Moderna (NASDAQ:MRNA) Price Target Raised to $48.00 at Barclays - MarketBeat
Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment - BioSpace
Moderna, Inc. (NASDAQ:MRNA) Given Consensus Recommendation of "Reduce" by Brokerages - marketbeat.com
Moderna, Inc. Trade Ideas — BSESOF:0QF - TradingView
What's Going On With Pfizer Stock Wednesday?BioNTech (NASDAQ:BNTX), Pfizer (NYSE:PFE) - Benzinga
Moderna, Inc. Trade Ideas — EUROTLX:4MRNA - TradingView
Barclays Adjusts Price Target on Moderna to $48 From $25, Maintains Equalweight Rating - marketscreener.com
Moderna (MRNA) Valuation Check As Patent Dispute Settlement And Cancer Therapy Pivot Refocus Investor Attention - Yahoo Finance
Moderna, Pfizer Want Bayer's COVID-Shot Patent Suits Tossed - Law360
Moderna (MRNA) Experiences Bearish Sentiment Among Option Traders - GuruFocus
Moderna, Pfizer Press to Toss Bayer’s Covid-Shot Patent Suits - Bloomberg Law News
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability - FinancialContent
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA) - dnj.com
Moderna, Inc. (MRNA) Stock Forecasts - Yahoo Finance
3 Companies Built Their Fortunes on COVID Vaccines, but Only 1 Has a Real Plan for What Comes Next - 24/7 Wall St.
Moderna's Spikevax Vaccine: Current Market Position, Strategic Developments and Investor Relevance i - AD HOC NEWS
EMA panel recommendation for mCOMBRIAX approval sees Moderna stock fall 7.49% - Traders Union
MRNA Stock Quote Price and Forecast - CNN
Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Moderna shares slide as investors weigh recent legal-cost clarity against fresh regulatory uncertainty - Quiver Quantitative
Stock Traders Purchase Large Volume of Moderna Call Options (NASDAQ:MRNA) - marketbeat.com
Moderna Inc (MRNA) 財務データ
収益
当期純利益
現金流量
EPS
0.95%
3.83%
大文字化:
|
ボリューム (24 時間):